South Korea

Pharmicell Co.,Ltd.

An EMIS Company Report EMIS is a Euromoney Institutional Investor plc company USD 29.95 Industry: Chemical Manufacturing Available in: English Format: PDF Download Most recent financial data: 2016 Buy full report

What’s included?

This report extracts all available information about Pharmicell Co.,Ltd. from EMIS' database of company information. The Table of Contents on the right indicates the categories of information that will be included in your report upon purchase.

Download a sample report

Company Tear Sheet (locked content will be provided in the purchased report)

Contact Information

Headquarters
874, Eonju-ro Gangnam-gu Seoul
Seoul; Seoul; Map
Postal Code: 135811

Tel: 02-3496-
Fax: 02-3496-

Company Description
Pharmicell Co.,Ltd. is engaged in manufacturing biopharmaceutical medicines used in curing diseases including cancer, brain, heart diseases and nervous system disorder. The company operates in four business divisions: Stem Cell area is engaged in manufacturing cell therapeutics and stem cell therapeutics ; Bio-based area is engaged in conducting stem cell research; Chemical area is engaged in manufacturing nucleosides, mPEGs, flame retardants, intermediates including TPC, BPDO, IDB-BPD, Carbapenem intermediates, among others; and Cosmetics area is engaged in manufacturing beauty products including counter aging solution, counter aging cream, toner, eye-cream, emulsions, and others. Pharmicell Co.,Ltd. is based in Seoul, South Korea. The company was incorporated in 1968 formerly known as FCB Twelve Co., Ltd.
NAICS Industry Classification
Main Activities: Chemical Manufacturing | Pharmaceutical and Medicine Manufacturing | Soap, Cleaning Compound, and Toilet Preparation Manufacturing
Basic Information
Total Employees:
121 (2018)
Outstanding Shares:
: ()
Registered Capital:
()
Financial Auditors:
()
Incorporation Date:
August 20, 1968
Profile Updated:
January 02, 2018
Key Executives
CEO
CEO
Non-Executive Independent Director
Auditor
Managing Director
More
Ownership Details
Kim,Hyun Soo
9%
Key Financial Highlights
2017 Q2C
Net sales revenue
Total operating revenue
Operating profit (EBIT)
EBITDA
Net Profit (Loss) for the Period
Total assets 99,512,326
Total equity
Operating Profit (EBIT) Margin
Return on Sales (ROS)
Return on Equity (ROE)
Debt to Equity
Quick Ratio
Cash Ratio
Note: units in Thousands. Statement: Audited, Individual
Source: NICE Information Service , EMIS Company Database.
Financial Performance Charts
Top Competitors

Financial Statements

Annual Statements

EMIS Credit Analytics

EMIS Benchmark Score

Latest News (Not included in the report)

Enterprise ACCESS

If you need regular and ongoing access to company information, you should consider a subscription to the full EMIS service.

EMIS company profiles are part of a larger information service where that combines company, industry and country data and analysis for over 125 emerging markets on a unique information platform.

REQUEST A DEMO

To view more information, REQUEST A DEMO